Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) has issued an update.
Amplia Therapeutics Limited has released a presentation at the Bioshares Biotech Summit, highlighting their focus on targeting pancreatic cancer through their pipeline of Focal Adhesion Kinase (FAK) inhibitors. This strategic move underscores the company’s commitment to advancing treatments for fibrotic cancers and could potentially enhance its position in the biotech industry by addressing significant unmet medical needs.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focusing on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company is particularly focused on fibrotic cancers such as pancreatic and ovarian cancer, and FAK’s role in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 7,323,863
Technical Sentiment Signal: Buy
Current Market Cap: A$116.8M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.